EUVIMEDEUVIMED entdecken
Multizentrische Studie

MRI ‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization

Weilang Wang, Xiuming Zhang, Yixing Yu, Feng Feng, Wu Cai, Shuwei Zhou, Shuhang Zhang, Binrong Li, Tianyi Xia, Shenghong Ju, Yuan-Cheng Wang iD

Liver International · 2026

DOI: 10.1111/liv.70481 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Weilang Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Zhongda Hospital, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, School…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Magnetic Resonance Imaging. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Predicting retreatment response of viable tumours after transarterial chemoembolization (TACE) is critical for personalised treatment and prognosis assessment in hepatocellular carcinoma (HCC). We aimed to develop an MRI‐based prediction model for viable tumour response.

Methods

This retrospective multicentre study included patients with HCC who presented with viable tumours 1 month after initial TACE between February 2015 and October 2022. In addition, data from a prospective clinical trial were reanalyzed as an external validation cohort. All patients underwent contrast‐enhanced MRI at baseline (for initial HCC assessment), at 1 month (for evaluation of viable tumour characteristics) and at 6 months (for assessment of treatment response). The training set ( n = 167) and test set ( n = 59) were used to build lesion‐ and patient‐level models predicting retreatment response at 6 months via logistic regression. Risk groups were stratified by the Youden index and analysed across retreatment subgroups.

Results

The Viable tumour Imaging Traits for Assessing Likelihood of response (VITAL) model incorporated four features: diffusion restriction ( p = 0.050; 1 point), peritumoral hyperenhancement ( p = 0.002; 1 point), heterogeneity ( p < 0.001; 2 points) and mural nodule ( p = 0.004; 2 points if absent). The model achieved AUCs of 0.821 (95% CI: 0.760–0.882) and 0.733 (95% CI: 0.602–0.865) in training and test cohorts. The patient‐level VITAL‐P Score was calculated as: 1 × (largest viable tumour size + viable tumour number) + 3 × VITAL Score. High‐risk patients (VITAL‐ p ≥ 16) had significantly shorter overall survival (OS) in the overall cohort ( p = 0.021) and shorter progression‐free survival (PFS)and OS compared with low‐risk patients in the locoregional therapy subgroup ( p = 0.021 and 0.002, respectively).

Conclusions

The prediction model based on imaging features of post‐TACE viable HCCs demonstrates strong predictive power for tumour retreatment response at 6 months and correlates well with prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticMagnetic Resonance ImagingHumansFemaleMaleRetrospective StudiesMiddle AgedAgedRetreatmentTreatment OutcomePrognosisPredictive Value of Tests

Stichwörter der Autor:innen

hepatocellular carcinomaretreatment responsetransarterial chemoembolizationviable tumour

Autor:innen und Institutionen

  • Department of Radiology, Zhongda Hospital, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, School of Medicine, Southeast University, Nanjing, China.
  • Department of Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
  • Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Radiology, Nantong Cancer Hospital, Nantong University, Nantong, China.
  • Department of Radiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.

ORCID-Profile: Yuan-Cheng Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, W., Zhang, X., Yu, Y., Feng, F., Cai, W., Zhou, S., Zhang, S., Li, B., Xia, T., Ju, S., & Wang, Y. C. (2026). MRI ‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization. Liver International. https://doi.org/10.1111/liv.70481

Vancouver

Wang W, Zhang X, Yu Y, Feng F, Cai W, Zhou S, et al. MRI ‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization. Liver International. 2026. doi:10.1111/liv.70481

BibTeX
@article{Wang2026,
  author = {Wang, Weilang and Zhang, Xiuming and Yu, Yixing and Feng, Feng and Cai, Wu and Zhou, Shuwei and Zhang, Shuhang and Li, Binrong and Xia, Tianyi and Ju, Shenghong and Wang, Yuan-Cheng},
  title = {MRI ‐Based Score to Predict Retreatment Response for Viable Hepatocellular Carcinomas After Transarterial Chemoembolization},
  journal = {Liver International},
  year = {2026},
  doi = {10.1111/liv.70481}
}
Kostenlos starten →